lncRNA MEG3作为miR-21的ceRNA在恶性肿瘤中的作用

doi:10.3760/cma.j.issn.1673-422X.2020.01.006

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (1): 35-38.doi: 10.3760/cma.j.issn.1673-422X.2020.01.006

lncRNA MEG3作为miR-21的ceRNA在恶性肿瘤中的作用

李醒, 黄俊星()

南通大学第五附属医院(江苏省泰州市人民医院)肿瘤科 225300

收稿日期:2019-12-06 修回日期:2019-12-13 出版日期:2020-01-08 发布日期:2020-03-22
通讯作者: 黄俊星 E-mail:hjxtz@sina.cn
基金资助:
江苏省医学创新团队项目(CXTDA2017042)

Role of lncRNA MEG3 as ceRNA of miR-21 in cancer

Li Xing, Huang Junxing()

Department of Oncology, Fifth Hospital Affiliated to Nantong University (Taizhou People's Hospital of Jiangsu Province), Taizhou 225300, China

Received:2019-12-06 Revised:2019-12-13 Online:2020-01-08 Published:2020-03-22
Contact: Huang Junxing E-mail:hjxtz@sina.cn
Supported by:
Medical Innovation Team Project of Jiangsu Province of China(CXTDA2017042)

摘要/Abstract

摘要：

长非编码RNA(lncRNA)-母系表达基因3(MEG3)和微小RNA-21(miR-21)是抑癌和致癌因子。竞争性内源RNA(ceRNA)假说为研究RNA之间的相互作用提供了新的策略。MEG3可作为miR-21的ceRNA在乳腺癌、宫颈癌、胃癌、肺癌、白血病等恶性肿瘤的发生、发展、增殖、转移以及药物耐药、预后中发挥重要作用。

关键词: 肿瘤, RNA, 长链非编码, 竞争性内源RNA, 母系表达基因3

Abstract:

Long non-coding RNA (lncRNA)-maternally expressed gene 3 (MEG3) and microRNA-21 (miR-21) have been widely recognized as tumor suppressor and promoter. The competing endogenous RNA (ceRNA) hypothesis provides a new strategy for studying the interaction of RNAs. In recent years, studies have shown that MEG3 can play an important role in the occurrence, development, proliferation, metastasis, drug resistance and prognosis of breast cancer, cervical cancer, gastric cancer, lung cancer, leukemia and other malignant tumors as the ceRNA of miR-21.

Key words: Neoplasms, RNA, long noncoding, Competing endogenous RNA, Maternally expressed gene 3

李醒, 黄俊星. lncRNA MEG3作为miR-21的ceRNA在恶性肿瘤中的作用[J]. 国际肿瘤学杂志, 2020, 47(1): 35-38.

Li Xing, Huang Junxing. Role of lncRNA MEG3 as ceRNA of miR-21 in cancer[J]. Journal of International Oncology, 2020, 47(1): 35-38.

参考文献 27

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492.
[2]	Salmena L, Poliseno L, Tay Y , et al. A ceRNA hypojournal: the Rosetta Stone of a hidden RNA language?[J]. Cell, 2011,146(3):353-358. DOI: 10.1016/j.cell.2011.07.014.
[3]	Greife A, Knievel J, Ribarska T , et al. Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma[J]. Clin Epigenetics, 2014,6(1):29. DOI: 10.1186/1868-7083-6-29.
[4]	Cui X, Jing X, Long C , et al. Long noncoding RNA MEG3, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis[J]. Oncotarget, 2017,8(12):19049-19056. DOI: 10.18632/oncotarget.14987.
[5]	Zhang J, Lin Z, Gao Y , et al. Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer[J]. J Exp Clin Cancer Res, 2017,36(1):5. DOI: 10.1186/s13046-016-0472-2.
[6]	Guo W, Dong Z, Liu S , et al. Promoter hypermethylation-mediated downregulation of miR-770 and its host gene MEG3, a long non-coding RNA, in the development of gastric cardia adenocarcinoma[J]. Mol Carcinog, 2017,56(8):1924-1934. DOI: 10.1002/mc.22650.
[7]	Gao Y, Huang P, Zhang J . Hypermethylation of MEG3 promoter correlates with inactivation of MEG3 and poor prognosis in patients with retinoblastoma[J]. J Transl Med, 2017,15(1):268. DOI: 10.1186/s12967-017-1372-8.
[8]	Ivo D'Urso P, Fernando D'Urso O, Damiano Gianfreda C , et al. miR-15b and miR-21 as circulating biomarkers for diagnosis of glioma[J]. Curr Genomics, 2015,16(5):304-311. DOI: 10.2174/1389202916666150707155610.
[9]	Han JG, Jiang YD, Zhang CH , et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer[J]. Ann Surg Treat Res, 2017,92(2):55-66. DOI: 10.4174/astr.2017.92.2.55.
[10]	Zhang CY, Yu MS, Li X , et al. Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway[J]. Tumour Biol, 2017,39(6):1010428317701311. DOI: 10.1177/1010428317701311.
[11]	Zhu M, Wang X, Gu Y , et al. MEG3 overexpression inhibits the tumorigenesis of breast cancer by downregulating miR-21 through the PI3K/Akt pathway[J]. Arch Biochem Biophys, 2019,661:22-30. DOI: 10.1016/j.abb.2018.10.021.
[12]	Zhang J, Yao T, Wang Y , et al. Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21[J]. Cancer Biol Ther, 2016,17(1):104-113. DOI: 10.1080/15384047.2015.1108496.
[13]	Ferlay J, Soerjomataram I, Dikshit R , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015,136(5):E359-E386. DOI: 10.1002/ijc.29210.
[14]	Dan J, Wang J, Wang Y , et al. LncRNA-MEG3 inhibits proliferation and metastasis by regulating miRNA-21 in gastric cancer[J]. Biomed Pharmacother, 2018,99:931-938. DOI: 10.1016/j.biopha.2018.01.164.
[15]	He Z, Dong W, Li Q , et al. Sauchinone prevents TGF-β-induced EMT and metastasis in gastric cancer cell[J]. Biomed Pharmacother, 2018,101:355-361. DOI: 10.1016/j.biopha.2018.02.121.
[16]	Xu G, Meng L, Yuan D , et al. MEG3/miR-21 axis affects cell mobility by suppressing epithelial mesenchymal transition in gastric cancer[J]. Oncol Rep, 2018,40(1):39-48. DOI: 10.3892/or.2018.6424.
[17]	Siegel R, Ma J, Zou Z , et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014,64(1):9-29. DOI: 10.3322/caac.21208.
[18]	Mizugaki H, Fujiwara Y, Yamamoto N , et al. Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases[J]. Jpn J Clin Oncol, 2014,44(9):835-840. DOI: 10.1093/jjco/hyu092.
[19]	Wang P, Chen D, Ma H , et al. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis[J]. Onco Targets Ther, 2017,10:5137-5149. DOI: 10.2147/OTT.S146423.
[20]	Oh KY, Hong KO, Huh YS , et al. Decreased expression of SOX7 induces cell proliferation and invasion and correlates with poor prognosis in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2017,46(9):752-758. DOI: 10.1111/jop.12566.
[21]	Man CH, Fung TK, Wan H , et al. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia[J]. Blood, 2015,125(25):3928-3936. DOI: 10.1182/blood-2014-06-580993.
[22]	Zhao T, Yang H, Tian Y , et al. SOX7 is associated with the suppression of human glioma by HMG-box dependent regulation of Wnt/β-catenin signaling[J]. Cancer Lett, 2016,375(1):100-107. DOI: 10.1016/j.canlet.2016.02.044.
[23]	Han L, Wang W, Ding W , et al. MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7[J]. J Cell Mol Med, 2017,21(9):2000-2008. DOI: 10.1111/jcmm.13120.
[24]	Jabbour E, Kantarjian H . Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management[J]. Am J Hematol, 2014,89(5):547-556. DOI: 10.1002/ajh.23691.
[25]	Li Z, Yang L, Liu X , et al. Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21[J]. Biomed Pharmacother, 2018,104:181-192. DOI: 10.1016/j.biopha.2018.05.047.
[26]	Li N, Zheng B, Cai HF , et al. Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China[J]. Clin Drug Investig, 2018,38(1):79-86. DOI: 10.1007/s40261-017-0587-z.
[27]	Zhou X, Yuan P, Liu Q , et al. LncRNA MEG3 regulates imatinib resistance in chronic myeloid leukemia via suppressing microRNA-21[J]. Biomol Ther (Seoul), 2017,25(5):490-496. DOI: 10.4062/biomolther.2016.162.

lncRNA MEG3作为miR-21的ceRNA在恶性肿瘤中的作用

Role of lncRNA MEG3 as ceRNA of miR-21 in cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.